01

ALK5 (TGF-βR1 ) Targeting Small Molecule Inhibitor

• A novel inhaled formulation of a specific treatment for idiopathic pulmonary fibrosis with higher selectivity compared to conventional TGF-βR1 (ALK5) inhibitors

02

Science & Innovation Features

• Small molecule with 2nd Gen. chemotype compared to 1st Gen. molecules that are currently undergoing clinical trials
• Novel compound with differentiated ALK family selectivity and strong efficacy
• Increase efficacy and minimize toxicity issue of IPF* treatment through topical action and inhalation development
  * IPF: Idiopathic Pulmonary Fibrosis

Hit/Lead Optimization -> Candidate Nomination

• Best-in-Class ALK5 inhibitory activity and selectivity
• Suitable solubility and permeability for inhalant formulation
• Avoid on-target toxicity by formulation and metabolism